

Integrating Structural and Dynamic Perspectives to Understand a Next-Gen Obesity Drug

Kenta Ishii, Dr Cindy Zhang, Dr Matthew Belousoff, and Prof Denise Wootten

Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria Australia

Abstract:

Obesity is one of the greatest health challenges our time, affecting approximately 1 in 8 adults worldwide [1]. It is a major driver of comorbidities, including type 2 diabetes, cardiovascular and kidney issues, fatty liver disease. Among available therapeutics, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have emerged as leading options due to their superior weight loss efficacy, metabolic benefits, and safety. The next generation of GLP-1RAs extends beyond GLP-1R agonism. For example, retatrutide, a tri-agonist of GLP-1R, the glucose dependent insulinotropic polypeptide receptor (GIPR) and the glucagon receptor (GCGR) has demonstrated unprecedented weight loss in clinical trials [2].

Here, we present three cryo-EM structures of retatrutide bound to GLP-1R, GIPR, and GCGR in complex with Gs, providing atomic-level insights into its receptor-specific binding modes. Using 3D variability analysis, we further characterize conformational heterogeneity within cryo-EM datasets, and reveal differences in conformational dynamics relative to the native peptide bound receptor complexes.

Together, these results reveal both conserved and distinct mechanisms of receptor engagement by retatrutide, offering a structural framework and insights into receptor dynamics underlying its multi-receptor engagement.

1. World Health Organization, *Obesity and overweight*. 2022.
2. Jastreboff, A.M., et al., *Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial*. N Engl J Med, 2023. **389**(6): p. 514-526.